title: Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis.
abstract: Immunohistochemical methods have been widely used to determine the histogenesis of spontaneous and chemically-induced mouse lung tumors. Typically, antigens for either alveolar Type II cells or bronchiolar epithelial Clara cells are studied. In the present work, the morphological and immunohistochemical phenotype of a transgenic mouse designed to develop lung tumors arising from Clara cells was evaluated. In this model, Clara cell-specific transformation is accomplished by directed expression of the SV40 large T antigen (TAg) under the mouse Clara cell secretory protein (CC10) promoter. In heterozygous mice, early lesions at 1 month of age consisted of hyperplastic bronchiolar epithelial cells. These progressed to adenoma by 2 months as proliferating epithelium extended into adjacent alveolar spaces. By 4 months, a large portion of the lung parenchyma was composed of tumor masses. Expression of constitutive CC10 was diminished in transgenic animals at all time points. Only the occasional cell or segment of the bronchiolar epithelium stained positively for CC10 by immunohistochemistry, and all tumors were found to be uniformly negative for staining. These results were corroborated by Western blotting, where CC10 was readily detectable in whole lung homogenate from nontransgenic animals, but not detected in lung from transgenic animals at any time point. Tumors were also examined for expression of surfactant apoprotein C (SPC), an alveolar Type II cell-specific marker, and found to be uniformly negative for staining. These results indicate that, in this transgenic model, expression of CC10, which is widely used to determine whether lung tumors arise from Clara cells, was reduced and subsequently lost during Clara cell tumor progression.
authors.affiliation: Central Product Safety, Procter and Gamble Company, Miami Valley Laboratories, PO Box 538707, Cincinnati, OH 45253, USA.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Hicks
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Vassallo
authors.forename: Matthew Z
authors.initials: MZ
authors.lastname: Dieter
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Lewis
authors.forename: Laurence O
authors.initials: LO
authors.lastname: Whiteley
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Fix
authors.forename: Lois D
authors.initials: LD
authors.lastname: Lehman-McKeeman
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000502:physiology; D001980:Bronchi / Q000276:immunology / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D002472:Cell Transformation, Viral / Q000235:genetics; D004195:Disease Models, Animal; D015870:Gene Expression; D005838:Genotype; D006579:Heterozygote; D006965:Hyperplasia / Q000473:pathology; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D011401:Promoter Regions, Genetic; D011506:Proteins / Q000276:immunology* / Q000378:metabolism*; D013997:Time Factors; D014598:Uteroglobin
chemical_list: D000952:Antigens, Polyomavirus Transforming; D011506:Proteins; C556390:Scgb1a1 protein, mouse; D014598:Uteroglobin